1. Home
  2. MPT vs BEAM Comparison

MPT vs BEAM Comparison

Compare MPT & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MPT

Medical Properties Trust Inc. common stock

N/A

Current Price

$5.20

Market Cap

3.1B

Sector

Real Estate

ML Signal

N/A

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$32.05

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MPT
BEAM
Founded
2003
2017
Country
United States
United States
Employees
121
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
3.0B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
MPT
BEAM
Price
$5.20
$32.05
Analyst Decision
Hold
Buy
Analyst Count
1
12
Target Price
$5.00
$50.75
AVG Volume (30 Days)
4.8M
2.0M
Earning Date
04-30-2026
05-06-2026
Dividend Yield
6.43%
N/A
EPS Growth
N/A
82.31
EPS
N/A
N/A
Revenue
N/A
$24,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.91
$33.77
P/E Ratio
N/A
N/A
Revenue Growth
N/A
33.33
52 Week Low
$4.51
$15.60
52 Week High
$6.47
$36.44

Technical Indicators

Market Signals
Indicator
MPT
BEAM
Relative Strength Index (RSI) 55.59 59.45
Support Level $4.86 $22.59
Resistance Level $6.47 $32.74
Average True Range (ATR) 0.17 2.20
MACD 0.01 0.07
Stochastic Oscillator 65.84 91.84

Price Performance

Historical Comparison
MPT
BEAM

About MPT Medical Properties Trust Inc. common stock

Medical Properties Trust Inc acquires and develops net-leased healthcare facilities. Its investments in healthcare real estate, other loans, and any investments in tenants are considered a single reportable segment. Its business strategy is to acquire and develop healthcare facilities and lease the facilities to healthcare operating companies under long-term net leases, which require the tenant to bear of the costs associated with the property. The group's geographic areas are the United States, the United Kingdom, and All other countries.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

Share on Social Networks: